Request Deal Involvement

Journey Medical to acquire the molecule stabilizing technology of VYNE Therapeutics for $475m.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Skadden Arps Slate Meagher & Flom

legal advisors

Skadden Arps Slate Meagher & Flom

Guggenheim Partners

financial advisors

Guggenheim Partners

LifeSci Partners

pr advisors

LifeSci Partners

or

Principals

VYNE THERAPEUTICS INC

vendor

VYNE THERAPEUTICS INC

VYNE THERAPEUTICS (MOLECULE STABILIZATION TECHNOLOGY)

target

VYNE THERAPEUTICS (MOLECULE STABILIZATION TECHNOLOGY)

JOURNEY MEDICAL CORPORATION

bidder

JOURNEY MEDICAL CORPORATION

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite